Skip to main content

Table 1 summarizes dose prescriptions and constraints for stereotactic body radiotherapy as described in the current literature

From: Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

Study/
Reference
Prescibed doses Rectum Urethra
Herrera et al. [38] 36.25 Gy (prostate) / 45–50 Gy (boost) V25Gy < 20 cc   D1cc < 38 Gy D0.1cc < 41 Gy   D1cc < 39 Gy D0.1cc < 41
Hypo-FLAME [37] 35 Gy (prostate) / 50 Gy (boost) V28Gy < 20% D2cc < 35 Gy D1cc < 38 Gy D0.035cc < 40 Gy    D0.035cc < 42 Gy
Zelefsky et al. [41] 35–40 Gy (prostate) V24Gy < 53%*   D1cc* < 38.5 Gy Dmax < 41.2 Gy    
PACE B [5] 36.25 Gy (prostate) V29Gy < 20%   D1cc < 36 Gy    V42 Gy < 50%  
NRG GU005 (NCT03367702) 36.25 Gy (prostate) D0.03cc (Gy) < = 38.06 D3cc < = 34.4 D10% < =32.63 D20% < = 29 D50% < =38.06   
  Acceptable < 40 < 36 < 34 < 30 < 40   
American Association of Physicits in Medicine   V25Gy < 20 cc    Dmax < 38 Gy    
Study/
Reference
Bladder Penile bulb Small bowel
Herrera et al. [38] Dmedian < 20 Gy   D1cc < 41 Gy D0.1cc < 45     
Hypo-FLAME [37] V28Gy < 20% D5cc < 37 Gy D1cc < 42 Gy   D90% < 20 Gy   D5cc < 19.5 Gy D0.035cc < 35 Gy
Zelefsky et al. [41] V24Gy < 53%* D15cc < 18.3 Gy D1cc < 42 Gy Dmax < 42 Gy     
PACE B [5] V18.1 Gy < 40% D5cc < 37 Gy    V29.5 Gy < 50%    D1cc < 30 Gy
NRG GU005 (NCT03367702) D0.03cc < =38.06 D50% < =18.12      D0.03cc < =30  
  Acceptable: < 40 Gy < 20 Gy      <  33 Gy  
American Association of Physicits in Medicine   D15cc < 18.3 Gy   Dmax < 38 Gy D3cc < 30 Gy Dmax < 50 Gy D5cc < 19.5 Gy D0.035cc < 35 Gy